|
Quinolines and derivatives
(total related compounds in database) |
| |
|
| (2R,3S,4S,5S,6R)-2-[(R)-hydroxy-(4-isoquinolin-5-yl-2-methylphenyl)methyl]-6-(hydroxymethyl)oxane-3,4,5-triol |
|
Escherichia |
Type 1 fimbriae |
Preclinical (in vivo) |
Mydock-McGrane L, et al. 2016. J Med Chem |
|
| (2R,3S,4S,5S,6R)-2-[(R)-[4-(1-aminoisoquinolin-7-yl)-2-methylphenyl]-hydroxymethyl]-6-(hydroxymethyl)oxane-3,4,5-triol |
|
Escherichia |
Type 1 fimbriae |
Preclinical (in vivo) |
Mydock-McGrane L, et al. 2016. J Med Chem |
|
| 7-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)isoquinolin-1-amine |
|
Escherichia |
Type 1 fimbriae |
Preclinical (in vivo) |
Mydock-McGrane L, et al. 2016. J Med Chem |
|
| 7-[4-[(R)-hydroxy-[(2R,3S,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]methyl]-3-methylphenyl]-2H-isoquinolin-1-one |
|
Escherichia |
Type 1 fimbriae |
Preclinical (in vivo) |
Mydock-McGrane L, et al. 2016. J Med Chem |
|
| 7-[4-[(R)-hydroxy-[(2R,3S,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]methyl]-3-methylphenyl]-3,4-dihydro-2H-isoquinolin-1-one |
|
Escherichia |
Type 1 fimbriae |
Preclinical (in vivo) |
Mydock-McGrane L, et al. 2016. J Med Chem |
|
| 2-[4-[3-(furan-2-yl)-5-phenyl-1,2-oxazol-4-yl]phenyl]quinoline-4-carboxylic acid |
|
Escherichia
Salmonella |
TTSS (Type III secretion system)
TTSS (SPI-2 encode) |
Preclinical (in vitro)
Preclinical (in vitro) |
El Qaidi S, et al. 2018. Front Cell Infect Microbiol
|
|
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
|
NOTE: for more interactive and statistic charts, please visit the JavaScript-rich interface of VFDB.
 |
| Back to top |
|
